• 1
    Thomas D, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005; 9: 383398.
  • 2
    Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2005; 20: 1735.
  • 3
    Feld J, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436: 967972.
  • 4
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • 5
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 6
    El Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127:(5 Suppl 1 ) S27S34.
  • 7
    Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998; 282: 103107.
  • 8
    Perelson AS, Herrmann E, Micol F, Zeuzem S. New kinetic models for the hepatitis C virus. HEPATOLOGY 2005; 42: 749754.
  • 9
    Lam NP. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. HEPATOLOGY 1997; 26: 226231.
  • 10
    Bigger CB, Brasky KM, Lanford RE. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol 2001; 75: 70597066.
  • 11
    Bigger CB, Guerra B, Brasky KM, Hubbard G, Beard MR, Luxon BA, et al. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol 2004; 78: 1377913792.
  • 12
    Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A 2002; 99: 1566915674.
  • 13
    Chen LM, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005; 128: 14371444.
  • 14
    Helbig KJ, Lau DTY, Semendric L, Harley HAJ, Beard MR. Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector. HEPATOLOGY 2005; 42: 702710.
  • 15
    Smith MW, Yue ZN, Korth MJ, Do HA, Boix L, Fausto N, et al. Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers. HEPATOLOGY 2003; 38: 14581467.
  • 16
    Ji X, Cheung R, Cooper S, Li Q, Greenberg HB, He XS. Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. HEPATOLOGY 2003; 37: 610621.
  • 17
    Jaekel E, Cornberg M, Mayer J, Koerbel JN, Wedemeyer H, Schueler A, et al. Early treatment of acute hepatitis C infection with interferon-alpha-2B monotherapy prevents develoment of chronic HCV infection. N Engl J Med 2001; 345: 16.
  • 18
    Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000; 290: 19721974.
  • 19
    Lanford RE, Guerra B, Lee H, Averett DR, Pfeiffer B, Chavez D, et al. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(I)-poly(C), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. J Virol 2003; 77: 10921104.
  • 20
    Lohmann V, Körner F, Koch JO, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110113.
  • 21
    Demers GW, Sugarman BJ, Beltran JC, Westreich LN, Iqbal Ahmed CM, Lau JY, et al. Interferon-a2b secretion by adenovirus-mediated gene delivery in rat, rabbit, and chimpanzee results in similar pharmacokinetic profiles. Toxicol Appl Pharmacol 2002; 180: 3642.
  • 22
    Lanford RE, Guerra B, Demers GW, Chang S, Sugarman BJ, Maneval DC, et al. Gene therapy for chronic hepatitis C based on adenoviral-mediated transfer of interferon-2b gene study based on the chimpanzee model. HEPATOLOGY 2000; 32( Suppl): 445A.
  • 23
    Lanford RE, Chavez D, Notvall L, Brasky KM. Comparison of tamarins and marmosets as hosts for GBV-B infections and the effect of immunosuppression on duration of viremia. Virology 2003; 311: 7280.
  • 24
    Lanford RE, Estlack LE. A cultivation method for highly differentiated primary chimpanzee hepatocytes permissive for hepatitis C virus replication. Methods Mol Med 1998; 19: 501516.
  • 25
    Malakhova OA, Yan M, Malakhov MP, Yuan Y, Ritchie KJ, Kim KI, et al. Protein ISGylation modulates the JAK-STAT signaling pathway. Genes Dev 2003; 17: 455460.
  • 26
    D'Cunha J, Knight EJ, Haas AL, Truitt RL, Borden EC. Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc Natl Acad Sci U S A 1996; 93: 211215.
  • 27
    Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004; 5: 699701.
  • 28
    Foy E, Li K, Sumpter R, Loo YM, Johnson CL, Wang CF, et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci U S A 2005; 102: 29862991.
  • 29
    Foy E, Li K, Wang CF, Sumpter R, Ikeda M, Lemon SM, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003; 300: 11451148.
  • 30
    Xu LG, Wang YY, Han KJ, Li LY, Zhai Z, Shu HB. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol Cell 2005; 19: 727740.
  • 31
    Seth RB, Sun L, Ea CK, Chen ZJ. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-κB and IRF3. Cell 2005; 122: 669682.
  • 32
    Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, et al. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol 2005; 6: 981988.
  • 33
    Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005; 437: 11671172.
  • 34
    Yoneyama M, Kikuchi M, Matsumoto K, Imaizumi T, Miyagishi M, Taira K, et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol 2005; 175: 28512858.
  • 35
    Rothenfusser S, Goutagny N, DiPerna G, Gong M, Monks BG, Schoenemeyer A, et al. The RNA helicase Lgp2 inhibits TLR-independent sensing of viral replication by retinoic acid-inducible gene-I. J Immunol 2005; 175: 52605268.
  • 36
    Li K, Foy E, Ferreon JC, Nakamura M, Ferreon ACM, Ikeda M, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 2005; 102: 29922997.
  • 37
    Helbig KJ, Ruszkiewicz A, Semendirc K, Harley HAJ, McColl SR, Beard MR. Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation. HEPATOLOGY 2004; 39: 12201229.
  • 38
    Hokeness KL, Kuziel WA, Biron CA, Salazar-Mather TP. Monocyte chemoattractant protein-1 and CCR2 interactions are required for IFN-alpha/beta-induced inflammatory responses and antiviral defense in liver. J Immunol 2005; 174: 15491556.
  • 39
    Lanford RE, Guerra B, Chavez D, Bigger CB, Brasky KM, Wang XH, et al. Cross-genotype immunity to hepatitis C virus. J Virol 2004; 78: 15751581.
  • 40
    Geiss G, Jin G, Guo J, Bumgarner R, Katze MG, Sen G. A comprehensive view of regulation of gene expression by double-stranded RNA-mediated cell signaling. J Biol Chem 2001; 276: 3017830182.
  • 41
    Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A 1998; 95: 1562315628.
  • 42
    Hayashi J, Stoyanova R, Seeger C. The transcriptorne of HCV replicon expressing cell lines in the presence of alpha interferon. Virology 2005; 335: 264275.
  • 43
    Larner AC, Chaudhuri A, Darnell JE Jr. Transcriptional induction by interferon: new protein(s) determine the extent and length of the induction. J Biol Chem 1986; 261: 453459.
  • 44
    Friedman RL, Manly SP, McMahon A, Kerr IM, Stark GR. Transcriptional and postranscriptional regulation of interferon-induced gene expression in human cells. Cell 1984; 38: 745755.
  • 45
    Harada H, Fujita T, Miyamoto M, Kimura Y, Maruyama M, Furia A, et al. Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell 1989; 58: 729739.
  • 46
    Yamagata T, Nishida J, Tanaka S, Sakai R, Mitani K, Yoshida M, et al. A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon regulated genes. Mol Cell Biol 1996; 16: 12831294.
  • 47
    Nelson N, Marks MS, Driggers PH, Ozato K. Interferon consensus sequence-binding protein, a member of the interferon regulatory factor family, suppresses interferon-induced gene transcription. Mol Cell Biol 1993; 13: 588599.
  • 48
    Ungureanu D, Silvennoinen O. SLIM Trims STATs: Ubiquitin E3 ligases provide insights for specificity in the regulation of cytokine signaling. Sci STKE 2005; 2005: e49.
  • 49
    Fenner JE, Starr R, Cornish AL, Zhang JG, Metcalf D, Schreiber RD, et al. Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. Nat Immunol 2006; 7: 3339.